Developing game changing treatments and cell therapies for severe diseases

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

MORE ABOUT US

“We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating diseases.”

Professor Ann Logan,
Scientific Director, Neuregenix Ltd.

NEWS

14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
31 July 2018
TIKOMED is looking for a business project manager with great administrative skills
We are looking for you who are driven, focused and known to get things done.…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More

EVENTS

TIKOMED WILL SPEAK AT BIOTECH IN EUROPE FORUM
Date: 4 October 2018 - 5 October 2018
Venue: Congress Center
Read More
TIKOMED WILL BE SENDING TEAM TO BIO-EUROPE
Date: 5 November 2018 - 7 November 2018
Venue: Bella Center
Read More
MORE NEWS & EVENTS

SUBSCRIBE